Rankings
▼
Calendar
NVAX Q4 2024 Earnings — Novavax, Inc. Revenue & Financial Results | Market Cap Arena
NVAX
Novavax, Inc.
$2B
Q4 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$88M
-69.7% YoY
Gross Profit
$52M
58.5% margin
Operating Income
-$131M
-148.4% margin
Net Income
-$81M
-91.8% margin
EPS (Diluted)
$-0.51
QoQ Revenue Growth
+4.5%
Cash Flow
Operating Cash Flow
-$173M
Free Cash Flow
-$175M
Stock-Based Comp.
$10M
Balance Sheet
Total Assets
$1.6B
Total Liabilities
$2.2B
Stockholders' Equity
-$624M
Cash & Equivalents
$530M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$88M
$291M
-69.7%
Gross Profit
$52M
$142M
-63.8%
Operating Income
-$131M
-$184M
+28.6%
Net Income
-$81M
-$178M
+54.6%
Revenue Segments
Product
$50M
56%
Royalties and Other
$39M
44%
Geographic Segments
Rest of the World
$40M
90%
Europe
$4M
10%
← FY 2024
All Quarters
Q1 2025 →